Primary neuroendocrine tumors of the ovary: Management and outcomes
Abstract Background There is currently no recognized first‐line treatment strategy for ovarian neuroendocrine tumors (NETs). Furthermore, because of the low incidence of ovarian NETs, no studies have reported prognostic statistics derived from large samples. This retrospective study aimed to investi...
Guardado en:
Autores principales: | Li Pang, Zhiqiang Guo |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4e7bed3ec3234d74ada074377a0183da |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors
por: Marta Opalińska, et al.
Publicado: (2021) -
Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): study protocol for a multicenter single-arm trial
por: Sebastian Krug, et al.
Publicado: (2021) -
Management of Ovarian Yolk Sac Tumor in Pregnancy in a Limited Resource Setting: Case Report
por: Tofan Utami, et al.
Publicado: (2021) -
Clinical Approach to Neuroendocrine Neoplasm Associated With Ovarian Teratoma
por: Marta Opalińska, et al.
Publicado: (2021) -
Imaging of Neuroendocrine Prostatic Carcinoma
por: Ahmed Taher, et al.
Publicado: (2021)